SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    B. Tombal, Assessing the benefit of bone-targeted therapies in prostate cancer, is the devil in the end point's definition?, Annals of Oncology, 2015, 26, 2, 257

    CrossRef

  2. 2
    Daniel L. Suzman, Sosipatros A. Boikos, Michael A. Carducci, Bone-targeting agents in prostate cancer, Cancer and Metastasis Reviews, 2014, 33, 2-3, 619

    CrossRef

  3. 3
    Stavros Sfoungaristos, Stephen J Frank, Mordechai Duvdevani, Ofer N Gofrit, Vladimir Yutkin, Ran Katz, Dov Pode, Petros Perimenis, Contemporary pharmacotherapy for the prevention of skeletal complications in patients with prostate cancer, Expert Opinion on Pharmacotherapy, 2014, 15, 17, 2513

    CrossRef

  4. 4
    Geoffrey T. Gotto, Changhong Yu, Melanie Bernstein, James A. Eastham, Michael W. Kattan, Development of a Nomogram Model Predicting Current Bone Scan Positivity in Patients Treated with Androgen-Deprivation Therapy for Prostate Cancer, Frontiers in Oncology, 2014, 4,

    CrossRef

  5. 5
    J. Fang, Q. Xu, Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics, Clinical and Translational Oncology, 2014,

    CrossRef

  6. 6
    Lorenz C Hofbauer, Tilman D Rachner, Robert E Coleman, Franz Jakob, Endocrine aspects of bone metastases, The Lancet Diabetes & Endocrinology, 2014, 2, 6, 500

    CrossRef

  7. 7
    T.A. West, B.E. Kiely, M.R. Stockler, Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials, European Journal of Cancer, 2014, 50, 11, 1916

    CrossRef

  8. 8
    Jocelyn L. Wozney, Emmanuel S. Antonarakis, Growth factor and signaling pathways and their relevance to prostate cancer therapeutics, Cancer and Metastasis Reviews, 2014, 33, 2-3, 581

    CrossRef

  9. 9
    Jennifer Wu, Evan Yu, Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy, Cancer and Metastasis Reviews, 2014, 33, 2-3, 607

    CrossRef

  10. 10
    Benjamin A. Gartrell, Fred Saad, Managing bone metastases and reducing skeletal related events in prostate cancer, Nature Reviews Clinical Oncology, 2014, 11, 6, 335

    CrossRef

  11. 11
    Deborah Mukherji, Aurelius Omlin, Carmel Pezaro, Ali Shamseddine, Johann de Bono, Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics, Cancer and Metastasis Reviews, 2014,

    CrossRef

  12. 12
    D. Lorente, J.S. De Bono, Molecular alterations and emerging targets in castration resistant prostate cancer, European Journal of Cancer, 2014, 50, 4, 753

    CrossRef

  13. 13
    Jun Hyuk Hong, Isaac Y. Kim, Nonmetastatic Castration-Resistant Prostate Cancer, Korean Journal of Urology, 2014, 55, 3, 153

    CrossRef

  14. 14
    C Albany, N M Hahn, Novel bone-targeting agents in prostate cancer, Prostate Cancer and Prostatic Disease, 2014, 17, 2, 112

    CrossRef

  15. 15
    Vasiliki Pasoglou, Ahmed Larbi, Laurence Collette, Laurence Annet, François Jamar, Jean-Pascal Machiels, Nicolas Michoux, Bruno C. Vande Berg, Bertrand Tombal, Frederic E. Lecouvet, One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): Toward an upfront simplified “all-in-one” imaging approach?, The Prostate, 2014, 74, 5
  16. 16
    A. Brett Hauber, Jorge Arellano, Yi Qian, Juan Marcos González, Joshua D. Posner, Ateesha F. Mohamed, Francesca Gatta, Bertrand Tombal, Jean-Jacques Body, Patient preferences for treatments to delay bone metastases, The Prostate, 2014, 74, 15
  17. 17
    Alberto Briganti, Nazareno Suardi, Andrea Gallina, Firas Abdollah, Giacomo Novara, Vincenzo Ficarra, Francesco Montorsi, Predicting the risk of bone metastasis in prostate cancer, Cancer Treatment Reviews, 2014, 40, 1, 3

    CrossRef

  18. 18
    Fred Saad, Prostate cancer: Preventing metastasis to bone: is this the end of the story?, Nature Reviews Urology, 2014, 11, 5, 252

    CrossRef

  19. 19
    Xiyun Deng, Guangchun He, Junwen Liu, Feijun Luo, Xiaoning Peng, Shigang Tang, Zhiyong Gao, Qinlu Lin, Jill M. Keller, Tao Yang, Evan T. Keller, Recent advances in bone-targeted therapies of metastatic prostate cancer, Cancer Treatment Reviews, 2014, 40, 6, 730

    CrossRef

  20. 20
    P. N. Lara, B. Ely, D. I. Quinn, P. C. Mack, C. Tangen, E. Gertz, P. W. Twardowski, A. Goldkorn, M. Hussain, N. J. Vogelzang, I. M. Thompson, M. D. Van Loan, Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421, JNCI Journal of the National Cancer Institute, 2014, 106, 4, dju013

    CrossRef

  21. 21
    Bertrand Tombal, Zometa European Study (ZEUS): Another Failed Crusade for the Holy Grail of Prostate Cancer Bone Metastases Prevention?, European Urology, 2014,

    CrossRef

  22. 22
    F. Gomez-Veiga, J. Ponce-Reixa, S. Martinez-Breijo, J. Planas, J. Morote, Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition, Actas Urológicas Españolas (English Edition), 2013, 37, 5, 292

    CrossRef

  23. 23
    F. Gomez-Veiga, J. Ponce-Reixa, S. Martinez-Breijo, J. Planas, J. Morote, Avances en la prevención y el tratamiento de las metástasis óseas en cáncer de próstata. Papel de la inhibición de RANK/RANKL, Actas Urológicas Españolas, 2013, 37, 5, 292

    CrossRef

  24. 24
    David I Quinn, Catherine M Tangen, Maha Hussain, Primo N Lara, Amir Goldkorn, Carol M Moinpour, Mark G Garzotto, Philip C Mack, Michael A Carducci, J Paul Monk, Przemyslaw W Twardowski, Peter J Van Veldhuizen, Neeraj Agarwal, Celestia S Higano, Nicholas J Vogelzang, Ian M Thompson, Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial, The Lancet Oncology, 2013, 14, 9, 893

    CrossRef

  25. 25
    Laura Rosanò, Francesca Spinella, Anna Bagnato, Endothelin 1 in cancer: biological implications and therapeutic opportunities, Nature Reviews Cancer, 2013, 13, 9, 637

    CrossRef

  26. 26
    Lan Coffman, Collin Mooney, Jaeyoung Lim, Shoumei Bai, Ines Silva, Yusong Gong, Kun Yang, Ronald J. Buckanovich, Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells, Cancer Biology & Therapy, 2013, 14, 2, 184

    CrossRef

  27. 27
    Ning Shao, Yang Wang, Wen Yu Jiang, Di Qiao, Shi Ge Zhang, Ye Wu, Xiang Xiang Zhang, Jiu Ling Wang, Yi Ding, Ning Han Feng, Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer, International Journal of Cancer, 2013, 133, 7
  28. 28
    Frederic E. Lecouvet, Renaud Lhommel, Vasiliki Pasoglou, Ahmed Larbi, François Jamar, Bertrand Tombal, Novel imaging techniques reshape the landscape in high-risk prostate cancers, Current Opinion in Urology, 2013, 23, 4, 323

    CrossRef

  29. 29
    Arjun Muralidharan, Maree T. Smith, Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments, Inflammopharmacology, 2013, 21, 5, 339

    CrossRef

  30. 30
    K Miller, J W Moul, M Gleave, K Fizazi, J B Nelson, T Morris, F E Nathan, S McIntosh, K Pemberton, C S Higano, Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer, Prostate Cancer and Prostatic Diseases, 2013,

    CrossRef

  31. 31
    Richard A Zager, Ali C M Johnson, Dennis Andress, Kirsten Becker, Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury, Kidney International, 2013, 84, 4, 703

    CrossRef

  32. 32
    Francesco Pantano, Alice Zoccoli, Michele Iuliani, Marco Fioramonti, Gaetano Lanzetta, Giuseppe Tonini, Daniele Santini, Targeting Bone Metastases: New Drugs for New Targets, Clinical Reviews in Bone and Mineral Metabolism, 2013, 11, 3-4, 103

    CrossRef

  33. 33
    Samer-ul Haque, Hazel Welch, Marilena Loizidou, Handbook of Biologically Active Peptides, 2013,

    CrossRef

  34. 34
    Samer-ul Haque, Dion Morton, Hazel Welch, Biologics against cancer-specific receptors – challenges to personalised medicine from early trial results, Current Opinion in Pharmacology, 2012, 12, 4, 392

    CrossRef

  35. 35
    Dionysios J. Papachristou, Efthimia K. Basdra, Athanasios G. Papavassiliou, Bone Metastases: Molecular Mechanisms and Novel Therapeutic Interventions, Medicinal Research Reviews, 2012, 32, 3
  36. 36
    Donald E. Kohan, John G. Cleland, Lewis J. Rubin, Dan Theodorescu, Matthias Barton, Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?, Life Sciences, 2012, 91, 13-14, 528

    CrossRef

  37. 37
    Winald R. Gerritsen, Padmanee Sharma, Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy, Journal of Clinical Immunology, 2012, 32, 1, 25

    CrossRef

  38. 38
    C O'Hanlon Brown, J Waxman, Current management of prostate cancer: dilemmas and trials, The British Journal of Radiology, 2012, 85, special_issue_1, S28

    CrossRef

  39. 39
    Matthew R Smith, Fred Saad, Robert Coleman, Neal Shore, Karim Fizazi, Bertrand Tombal, Kurt Miller, Paul Sieber, Lawrence Karsh, Ronaldo Damião, Teuvo L Tammela, Blair Egerdie, Hendrik Van Poppel, Joseph Chin, Juan Morote, Francisco Gómez-Veiga, Tomasz Borkowski, Zhishen Ye, Amy Kupic, Roger Dansey, Carsten Goessl, Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial, The Lancet, 2012, 379, 9810, 39

    CrossRef

  40. 40
    Evan Y. Yu, Kurt Miller, Joel Nelson, Martin Gleave, Karim Fizazi, Judd W. Moul, Faith E. Nathan, Celestia S. Higano, Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer, The Journal of Urology, 2012, 188, 1, 103

    CrossRef

  41. 41
    Deborah Stuart, Sara Rees, Stephanie K Woodward, Robert Koesters, Kevin A Strait, Donald E Kohan, Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion, BMC Nephrology, 2012, 13, 1, 166

    CrossRef

  42. 42
    Daniel George, Judd W. Moul, Emerging treatment options for patients with castration-resistant prostate cancer, The Prostate, 2012, 72, 3
  43. 43
    Noel W. Clarke, Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer, BJU International, 2012, 110,
  44. 44
    N. Shore, M. Mason, Th. M. de Reijke, New developments in castrate-resistant prostate cancer, BJU International, 2012, 109,
  45. 45
    Celestia S. Higano, New treatment options for patients with metastatic castration-resistant prostate cancer, Cancer Treatment Reviews, 2012, 38, 5, 340

    CrossRef

  46. 46
    B. Tombal, Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient?, Annals of Oncology, 2012, 23, suppl 10, x251

    CrossRef

  47. 47
    Carsten-H. Ohlmann, Axel S. Merseburger, Henrik Suttmann, David Schilling, Lutz Trojan, Carsten Kempkensteffen, Stefan Corvin, Michael J. Mathers, Patrick J. Bastian, Novel options for the treatment of castration-resistant prostate cancer, World Journal of Urology, 2012, 30, 4, 495

    CrossRef

  48. 48
    Tilman D. Rachner, Peyman Hadji, Lorenz C. Hofbauer, Novel therapies in benign and malignant bone diseases, Pharmacology & Therapeutics, 2012, 134, 3, 338

    CrossRef

  49. 49
    Neveen Said, Dan Theodorescu, Permissive role of endothelin receptors in tumor metastasis, Life Sciences, 2012, 91, 13-14, 522

    CrossRef

  50. You have free access to this content50
    Joel B. Nelson, Karim Fizazi, Kurt Miller, Celestia Higano, Judd W. Moul, Hideyuki Akaza, Thomas Morris, Stuart McIntosh, Kristine Pemberton, Martin Gleave, Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone, Cancer, 2012, 118, 22
  51. 51
    Ajjai Alva, Susan Slovin, Stephanie Daignault, Michael Carducci, Robert DiPaola, Ken Pienta, David Agus, Kathleen Cooney, Alice Chen, David C. Smith, Maha Hussain, Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium, Investigational New Drugs, 2012, 30, 2, 749

    CrossRef

  52. 52
    Shin Ogita, Sheela Tejwani, Lance Heilbrun, Joseph Fontana, Elisabeth Heath, Stacy Freeman, Daryn Smith, Karen Baranowski, Ulka Vaishampayan, Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer, ISRN Oncology, 2012, 2012, 1

    CrossRef

  53. 53
    G. Colloca, Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: A review, Cancer Treatment Reviews, 2012, 38, 8, 1020

    CrossRef

  54. 54
    Y. Loriot, C. Massard, K. Fizazi, Recent developments in treatments targeting castration-resistant prostate cancer bone metastases, Annals of Oncology, 2012, 23, 5, 1085

    CrossRef

  55. 55
    A. J. Zurita, D. J. George, N. D. Shore, G. Liu, G. Wilding, T. E. Hutson, M. Kozloff, P. Mathew, C. S. Harmon, S. L. Wang, I. Chen, E. Chow Maneval, C. J. Logothetis, Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial, Annals of Oncology, 2012, 23, 3, 688

    CrossRef

  56. 56
    Niall M Corcoran, Martin E Gleave, Targeted therapy in prostate cancer, Histopathology, 2012, 60, 1
  57. 57
    Álvaro Pinto, María Merino, Pilar Zamora, Andrés Redondo, Beatriz Castelo, Enrique Espinosa, Targeting the endothelin axis in prostate carcinoma, Tumor Biology, 2012, 33, 2, 421

    CrossRef

  58. 58
    Guru Sonpavde, Giuseppe Di Lorenzo, Celestia S. Higano, Philip W. Kantoff, Ravi Madan, Neal D. Shore, The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature, European Urology, 2012, 61, 4, 639

    CrossRef

  59. 59
    Emmanuel S. Antonarakis, Michael A. Carducci, Mario A. Eisenberger, Campbell-Walsh Urology, 2012,

    CrossRef

  60. 60
    Flaminia Coluzzi, Analgesics for Cancer Pain, 2012,

    CrossRef

  61. 61
    Dominique Heymann, Advances in Bone Metastasis Management, 2012,

    CrossRef

  62. 62
    Saroj Niraula, Ian F. Tannock, Broadening horizons in medical management of prostate cancer, Acta Oncologica, 2011, 50, S1, 141

    CrossRef

  63. 63
    S. Leo, C. Accettura, V. Lorusso, Castration-Resistant Prostate Cancer: Targeted Therapies, Chemotherapy, 2011, 57, 2, 115

    CrossRef

  64. 64
    Se Joong Kim, Sun Il Kim, Current Treatment Strategies for Castration-Resistant Prostate Cancer, Korean Journal of Urology, 2011, 52, 3, 157

    CrossRef

  65. 65
    Tilman Todenhoefer, Georgios Gakis, David Schilling, Gerhard Feil, Christian Schwentner, Arnulf Stenzl, Diagnosis and treatment of prostate cancer-related bone disease, Clinical Investigation, 2011, 1, 2, 265

    CrossRef

  66. 66
    Matthew R. Smith, Richard Cook, Ker-Ai Lee, Joel B. Nelson, Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer, Cancer, 2011, 117, 10
  67. 67
    Flaminia Coluzzi, Ilenia Mandatori, Consalvo Mattia, Emerging therapies in metastatic bone pain, Expert Opinion on Emerging Drugs, 2011, 16, 3, 441

    CrossRef

  68. 68
    Rong Wang, Roderick H. Dashwood, Endothelins and their receptors in cancer: Identification of therapeutic targets, Pharmacological Research, 2011, 63, 6, 519

    CrossRef

  69. 69
    Megan N. Thobe, Robert J. Clark, Russell O. Bainer, Sandip M. Prasad, Carrie W. Rinker-Schaeffer, From Prostate to Bone: Key Players in Prostate Cancer Bone Metastasis, Cancers, 2011, 3, 4, 478

    CrossRef

  70. 70
    Rosamaria Lappano, Marcello Maggiolini, G protein-coupled receptors: novel targets for drug discovery in cancer, Nature Reviews Drug Discovery, 2011, 10, 1, 47

    CrossRef

  71. 71
    Alexander N. Shoushtari, Russell Z. Szmulewitz, Carrie W. Rinker-Schaeffer, Metastasis-suppressor genes in clinical practice: lost in translation?, Nature Reviews Clinical Oncology, 2011,

    CrossRef

  72. 72
    Irène Asmane, Jocelyn Céraline, Brigitte Duclos, Lynn Rob, Valère Litique, Philippe Barthélémy, Jean-Pierre Bergerat, Patrick Dufour, Jean-Emmanuel Kurtz, New Strategies for Medical Management of Castration-Resistant Prostate Cancer, Oncology, 2011, 80, 1-2, 1

    CrossRef

  73. 73
    Himisha Beltran, Tomasz M. Beer, Michael A. Carducci, Johann de Bono, Martin Gleave, Maha Hussain, William K. Kelly, Fred Saad, Cora Sternberg, Scott T. Tagawa, Ian F. Tannock, New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety, European Urology, 2011, 60, 2, 279

    CrossRef

  74. 74
    C. Nabhan, B. Parsons, E. Z. Touloukian, W. M. Stadler, Novel approaches and future directions in castration-resistant prostate cancer, Annals of Oncology, 2011, 22, 9, 1948

    CrossRef

  75. 75
    T. Nelius, K. Rinard, S. Filleur, Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer – Review of the literature, Cancer Treatment Reviews, 2011, 37, 6, 444

    CrossRef

  76. 76
    Donald L. Trump, Heather Payne, Kurt Miller, Johann S. de Bono, Joe Stephenson, Howard A. Burris, Faith Nathan, Maria Taboada, Thomas Morris, Andreas Hubner, Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer, The Prostate, 2011, 71, 12
  77. 77
    Heather Payne, Philip Cornford, Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer, Urologic Oncology: Seminars and Original Investigations, 2011, 29, 6, 593

    CrossRef

  78. 78
    Koji Hoshino, Hitoshi Ishiguro, Jun-ichi Teranishi, Shin-ichiro Yoshida, Satoshi Umemura, Yoshinobu Kubota, Hiroji Uemura, Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells, The Prostate, 2011, 71, 9
  79. You have free access to this content79
    A Bagnato, M Loizidou, BR Pflug, J Curwen, J Growcott, Role of the endothelin axis and its antagonists in the treatment of cancer, British Journal of Pharmacology, 2011, 163, 2
  80. 80
    Stephen J. Freedland, Screening, risk assessment, and the approach to therapy in patients with prostate cancer, Cancer, 2011, 117, 6
  81. 81
    Timothy A. Yap, Andrea Zivi, Aurelius Omlin, Johann S. de Bono, The changing therapeutic landscape of castration-resistant prostate cancer, Nature Reviews Clinical Oncology, 2011, 8, 10, 597

    CrossRef

  82. 82
    Joseph L. Sottnik, Jian Zhang, Jill A. Macoska, Evan T. Keller, The PCa Tumor Microenvironment, Cancer Microenvironment, 2011, 4, 3, 283

    CrossRef

  83. 83
    Michael A Carducci, Daniel Keizman, Targeted Therapies for Castration-Resistant Prostate Cancer, 2011,

    CrossRef

  84. 84
    Jens Schmitz, Ulrike Holzgrabe, Alte und neue Endothelin-Rezeptor-Antagonisten. PAH und viele andere Indikationen, Pharmazie in unserer Zeit, 2010, 39, 6
  85. 85
    Larissa A. Korde, Julie R. Gralow, Bone Disease in Breast Cancer: The Era of New Targeted Therapies, Current Breast Cancer Reports, 2010, 2, 1, 25

    CrossRef

  86. 86
    Dirk Schrijvers, Peter Van Erps, Jim Cortvriend, Castration-refractory prostate cancer: New drugs in the pipeline, Advances in Therapy, 2010, 27, 5, 285

    CrossRef

  87. 87
    Giuseppe Di Lorenzo, Carlo Buonerba, Riccardo Autorino, Sabino De Placido, Cora N. Sternberg, Castration-Resistant Prostate Cancer, Drugs, 2010, 70, 8, 983

    CrossRef

  88. 88
    Sebastian Stösser, Nitin Agarwal, Anke Tappe-Theodor, Masashi Yanagisawa, Rohini Kuner, Dissecting the functional significance of endothelin A receptors in peripheral nociceptors in vivo via conditional gene deletion, Pain, 2010, 148, 2, 206

    CrossRef

  89. 89
    M. D. Galsky, N. J. Vogelzang, Docetaxel-based combination therapy for castration-resistant prostate cancer, Annals of Oncology, 2010, 21, 11, 2135

    CrossRef

  90. 90
    D. Bianchini, A. Zivi, S. Sandhu, J. S. de Bono, Horizon scanning for novel therapeutics for the treatment of prostate cancer, Annals of Oncology, 2010, 21, Supplement 7, vii43

    CrossRef

  91. 91
    Allan Lipton, Implications of Bone Metastases and the Benefits of Bone-Targeted Therapy, Seminars in Oncology, 2010, 37, S15

    CrossRef

  92. 92
    A. Villers, Y. Neuzillet, P. Beuzeboc, Inhibiteurs du récepteur A de l’endothéline, Progrès en Urologie, 2010, 20, S77

    CrossRef

  93. 93
    Dale R. Shepard, Derek Raghavan, Innovations in the systemic therapy of prostate cancer, Nature Reviews Clinical Oncology, 2010, 7, 1, 13

    CrossRef

  94. 94
    Allan Lipton, New approaches to treating and preventing bone metastases, Current Opinion in Supportive and Palliative Care, 2010, 1

    CrossRef

  95. 95
    Emmanuel S. Antonarakis, Michael A. Carducci, Mario A. Eisenberger, Novel targeted therapeutics for metastatic castration-resistant prostate cancer, Cancer Letters, 2010, 291, 1, 1

    CrossRef

  96. 96
    Robyn J. Macfarlane, Kim N. Chi, Novel Targeted Therapies for Prostate Cancer, Urologic Clinics of North America, 2010, 37, 1, 105

    CrossRef

  97. 97
    Diletta Bianchini, Andrea Zivi, Shahneen Sandhu, Johann S de Bono, RETRACTED: Horizon scanning for novel therapeutics for the treatment of prostate cancer, Expert Opinion on Investigational Drugs, 2010, 19, 12, 1487

    CrossRef

  98. 98
    Michael A. Harding, Dan Theodorescu, RhoGDI signaling provides targets for cancer therapy, European Journal of Cancer, 2010, 46, 7, 1252

    CrossRef

  99. 99
    Karim Fizazi, Cora N. Sternberg, John M. Fitzpatrick, R. William Watson, Majid Tabesh, Role of targeted therapy in the treatment of advanced prostate cancer, BJU International, 2010, 105, 6
  100. 100
    Kurt Miller, Arnulf Stenzl, Bertrand Tombal, Advances in the Therapy of Prostate Cancer–Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL Pathways, European Urology Supplements, 2009, 8, 9, 747

    CrossRef

  101. 101
    Kim N. Chi, Anders Bjartell, David Dearnaley, Fred Saad, Fritz H. Schröder, Cora Sternberg, Bertrand Tombal, Tapio Visakorpi, Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets, European Urology, 2009, 56, 4, 594

    CrossRef

  102. 102
    Benjamin J Epstein, Shawn Anderson, Endothelin receptor antagonists as antihypertensives: the next frontier, Expert Review of Cardiovascular Therapy, 2009, 7, 6, 675

    CrossRef

  103. 103
    Joel B. Nelson, Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer, European Urology Supplements, 2009, 8, 1, 20

    CrossRef

  104. 104
    P F Mulders, J A Schalken, Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer, Prostate Cancer and Prostatic Diseases, 2009, 12, 3, 241

    CrossRef

  105. 105
    Matthew R. Smith, Gordon A. Brown, Fred Saad, New opportunities in the management of prostate cancer–related bone complications, Urologic Oncology: Seminars and Original Investigations, 2009, 27, 6, S1

    CrossRef

  106. 106
    David Y. Patten, Oliver Sartor, New Therapeutic Agents for Castration-Refractory Prostate Cancer, Clinical Genitourinary Cancer, 2009, 7, 2, E4

    CrossRef

  107. 107
    F. Finter, L. Rinnab, K. Gust, R. Küfer, Palliative Systemtherapie des kastrationsresistenten Prostatakarzinoms, Der Urologe, 2009, 48, 11, 1295

    CrossRef

  108. 108
    Karim Fizazi, Kurt Miller, SPECIFIC ENDOTHELIN-A RECEPTOR ANTAGONISM FOR THE TREATMENT OF ADVANCED PROSTATE CANCER, BJU International, 2009, 104, 10
  109. 109
    Nancy A. Dawson, Targeted therapy in prostate cancer—Are we our own worst enemy?, Cancer, 2008, 113, 9
  110. 110
    David J. Edmonds, Endothelin Antagonists for the Treatment of Pulmonary Arterial Hypertension,